Skip to main content
. Author manuscript; available in PMC: 2014 Aug 15.
Published in final edited form as: J Immunol. 2013 Jul 5;191(4):1948–1956. doi: 10.4049/jimmunol.1202092

Figure 1. Anti-CD40L mAb treatment prolongs the survival of vascularized skin allografts.

Figure 1

C3H mice were transplanted with a conventional B6 skin allograft (panel A), a vascularized B6 skin allograft (B) or a B6 heart (C) and injected intraperitoneally with PBS (dotted lines) or with anti-CD40L mAbs (MR1 given i.p., 0.5 mg at d0, and 2 and 4 post-transplantation) (solid lines). The results are shown as percent graft survival over time after transplantation. Four to eight mice were tested in each group. Graft survival was analyzed using the Kaplan-Meier method, and survival curves were compared using the log-rank test.